Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Launch of CTIS-Profile 2+ on Cantab Connect

Cambridge Cognition, (AIM: COG), which specialises in computerised neuropsychological tests, announces the launch of the Clinical Trials Information System -Profile 2+ ('CTIS-Profile 2+'). The new product enablesCambridge Cognition toprovide pharmaceutical and biotechnology companies with cognitive safety and tolerability testing across all phases of the clinical development of new therapeutic compounds; an addressable market estimated to be in excess of £105m.

CTIS-Profile 2+ is the latest product in the Company's safety and tolerability testing portfolio on the cloud computing platform, Cantab Connect, launched in June 2014. This productallows Cambridge Cognition to provideaccurate cognitive safety profiling in Phase II, III and IV clinical trials, complimentingtheir CTIS-Profile and CTIS-AL products, which provide cognitive safety testing in Phase I trials and measurement of the abuse potential for investigational drugs respectively.

All CTIS products have been designed for Good Clinical Practice-compliant studies. The products comply with the European Clinical Trials Directive 2001/20/EC and meet FDA regulations for computerised systems used in clinical trials and 21 CFR Part II.

Chief Scientific Officer of Cambridge Cognition, Dr Andrew Blackwell, commented: "Following on from the launch of CTIS-Profile there has been an increasing demand from our customers to provide sensitive, intuitive and rapid cognitive testing on the Cantab Connect platform. As well as significantly reducing data errors and the labor-intensity of trials, touchscreen assessment and electronic data capture increases confidence and accelerates decision making in the clinical trial process, delivering huge benefits to clients."

Chief Executive Officer of Cambridge Cognition, Nick Kerton, commented: "In June of this year we launched CTIS-Profile and CTIS-AL to provide cognitive safety assessments in phase I and abuse liability trials. With CTIS-Profile 2+ we now become the first company to offer sensitive cloud-based cognitive tests for safety and tolerability throughout all phases of drug development, enabling pharmaceutical and biotechnology companies to develop new therapies which are both safe for patients and compliant with regulators."